From March 29 to March 30, among the listed companies surveyed by institutions, Yantai Zhenghai Magnetic Material Co.Ltd(300224) , Shandong Jincheng Pharmaceutical Group Co.Ltd(300233) , Guiyang Xintian Pharmaceutical Co.Ltd(002873) received 119, 80 and 77 institutions respectively. The key points of the research are as follows.
Yantai Zhenghai Magnetic Material Co.Ltd(300224) research points: the company’s high-performance Nd-Fe-B permanent magnet material business has increased significantly and has entered the core supply chain of energy conservation and new energy market
On March 30, several institutions conducted research activities on Yantai Zhenghai Magnetic Material Co.Ltd(300224) ( Yantai Zhenghai Magnetic Material Co.Ltd(300224) . SZ). General manager Li Zhiqiang and deputy general manager song Kan answered questions from institutions.
Yantai Zhenghai Magnetic Material Co.Ltd(300224) mainly produces and sells various magnetic materials and related components. It is the main supplier of high-performance NdFeB permanent magnet materials in the fields of Shanxi Guoxin Energy Corporation Limited(600617) and energy conservation and environmental protection.
\u3000\u3000 1. The company’s business of high-performance NdFeB permanent magnet materials has increased significantly and has entered the core supply chain of energy conservation and new energy market
High performance NdFeB permanent magnet materials are mainly used in “three energy” high-end applications such as new energy, energy conservation and intelligence. In the downstream structure of the company’s products, the automobile market accounts for more than 50%, of which energy-saving and new energy vehicles account for more than 30%. At present, the company has fully entered the supply chain of world mainstream automobile enterprises.
The company’s energy-saving and new energy vehicle products have achieved mass production or fixed-point production among the top ten automobile manufacturers in the world. It is ranked as the first-class supplier of many automobile main engine plants such as Volkswagen, Toyota, Ford, Hyundai and Great Wall Motor Company Limited(601633) and has entered the core supply chain of many new forces such as ideal and Zero run.
\u3000\u3000 2. The gross profit margin of the business decreased year-on-year, but it will not affect the overall revenue of the company
Due to the long price adjustment cycle of automobile customers, the upstream and downstream price transmission is relatively slow, superimposing the impact of rising raw material prices, resulting in a year-on-year decline in the company’s gross profit margin. However, the business stability of the company’s automobile customers is good, which can guarantee the company’s long-term and stable income.
\u3000\u3000 3. The company has taken a number of measures to ensure the supply of raw materials
Mutual benefit and win-win, be a valuable partner: continue to deepen the established strategic cooperative relations with China rare earth group and North rare earth, and strengthen the cooperation with upstream partners while ensuring the long-term and stable supply of rare earth raw materials;
Combination of strategic procurement and dynamic procurement: adhere to the principle of determining production by sales, production by production, reasonable inventory, pay close attention to the market and determine inventory dynamically in combination with production demand;
Combination of direct procurement and recycling: strengthen the recycling management of self-produced Nd-Fe-B waste and improve the recycling capacity of rare earth resources.
\u3000\u3000 4。 the company’s sales performance in the automotive field increased significantly
In 2021, the company’s sales revenue in the field of energy-saving and new energy vehicle market increased by 110% year-on-year, and the delivery volume of motor magnets for energy-saving and new energy vehicles was 1.89 million sets, with a year-on-year increase of 97%; The sales revenue in the field of automotive electrification such as EPS increased by 67% year-on-year, and 24 million sets of magnets for automotive electrification motors such as EPS were delivered, with a year-on-year increase of 23%.
Shandong Jincheng Pharmaceutical Group Co.Ltd(300233) research points: the raw material glutathione is growing rapidly, and the promotion in non pharmaceutical fields may be increased in the future
On March 30, several institutions conducted research activities on Shandong Jincheng Pharmaceutical Group Co.Ltd(300233) ( Shandong Jincheng Pharmaceutical Group Co.Ltd(300233) . SZ) Shandong Jincheng Pharmaceutical Group Co.Ltd(300233) vice president and chairman secretary Zhu Xiaogang answered questions from the organization.
Shandong Jincheng Pharmaceutical Group Co.Ltd(300233) main business is mainly divided into three fields: pharmaceutical chemical industry, biopharmaceutical industry and pharmaceutical preparation. The company is one of the national high-tech enterprises.
\u3000\u3000 1. The company has made significant progress in three major sector projects
In terms of pharmaceutical intermediates, the market share of the main products of cephalosporin pharmaceutical intermediates is more than 50%. At present, it is in the leading position in the industry of cephalosporin pharmaceutical intermediates. In 2021, affected by the sharp rise in the price of raw materials, the production cost increased and the gross profit margin decreased. In 2022, the company raised the price of the main products of cephalosporin intermediates.
In the biopharmaceutical sector, the revenue will reach 4.5% in 2021 RMB 8.5 billion, with a net profit of RMB 170 million, with a year-on-year increase of 55%. In 2021, the sales volume of glutathione reached 312 tons, of which the sales volume in foreign markets increased by 45% year-on-year. In 2021, the sales volume of adenosylmethionine p-toluenesulfonate reached 45 tons and that of adenosylmethionine drug grade succinic disulfonate reached 20 tons. The sales volume in foreign markets increased significantly.
In terms of terminal preparations, Jincheng JinSu achieved a net profit of more than 94 million yuan in 2021, with a year-on-year increase of 84%. Among them, cefazolin sodium for injection and ceftazidime for injection won the fifth batch of national centralized procurement, and cefotaxime sodium for injection also won the procurement of Jiangxi Guangdong Henan Hubei alliance.
\u3000\u3000 2. Glutathione, the raw material drug, is growing rapidly and may be promoted in non pharmaceutical fields in the future
In 2021, the overseas market sales revenue increased by more than 40 million yuan compared with that in 2020. Glutathione is mainly taken orally in foreign markets. In the past two years, consumers in developed countries such as Europe and the United States have a strong desire to improve immunity.
Glutathione has a broad market space. In the future, it will be mainly promoted in non medicinal fields such as animal health, plant nutrition and Chinese health care products market.
\u3000\u3000 3. Drug grade adenosylmethionine will reach 180 tons after expansion, and the project review of adenosylmethionine for injection is in progress
Ademetionine butyrate disulfonate is mainly used for cholestasis. Ademetionine p-toluenesulfonate is used as a health product to improve mood in markets such as the United States and Europe.
In 2021, the sales volume of adenosylmethionine p-toluenesulfonate reached 45 tons and that of adenosylmethionine drug grade succinic disulfonate reached 20 tons. Adenosylmethionine has obtained the approval of Chinese api and is expanding its production capacity by 120 tons. The test run is expected to be completed by the end of June this year, and the capacity after expansion will reach 180 tons. It is expected that the newly increased capacity will be consumed in the next year.
Ademetionine succinate for injection has also submitted an application for registration and is currently under professional review.
Guiyang Xintian Pharmaceutical Co.Ltd(002873) research points: 60 national standard varieties of traditional Chinese medicine formula granules have been filed, and the company’s OTC market share may increase to 50% in the future
From March 29 to March 30, several institutions conducted research activities on Guiyang Xintian Pharmaceutical Co.Ltd(002873) ( Guiyang Xintian Pharmaceutical Co.Ltd(002873) . SZ).
Guiyang Xintian Pharmaceutical Co.Ltd(002873) deputy general manager and chairman secretary Wang Guangping answered questions from institutions.
Guiyang Xintian Pharmaceutical Co.Ltd(002873) is a national high-tech enterprise integrating new drug R & D, drug production and sales. It is mainly engaged in the research, development, production and sales of Chinese patent medicine products for the treatment of urinary system diseases, gynecological diseases and other diseases with complex etiology.
\u3000\u3000 1. 60 national standard varieties of traditional Chinese medicine formula granules have been filed
The company has completed the filing of 60 national standard varieties of traditional Chinese medicine formula granules, and the original Guizhou standard varieties are currently in normal sales.
Traditional Chinese medicine formula granules are still in the initial stage and account for a relatively small proportion in the three-year doubling plan. In 2022, the company will further strengthen the promotion, continue to complete the filing of national standard varieties, and improve the sales in the market in Guizhou Province,
\u3000\u3000 2. At present, the company’s OTC market accounts for about 30%, which may be increased to 50% in the future
At present, the company’s OTC market accounts for about 30%. The company will boost the rapid growth of OTC market on the basis of maintaining the stable growth of prescription drug market share.
The price of the company’s OTC products is relatively market-oriented. With the revenue of OTC market increasing year by year, the share of OTC market is expected to increase to 50% in the next few years, forming a two wheel drive development trend of hospital market and OTC market.
\u3000\u3000 3. In terms of R & D, the company has covered many varieties
(1) phase II clinical studies have been completed for three varieties, including LongQin penyushu granule, zhuyutong granule and Kue Jieyin capsule, and applications for marketing license will be submitted in succession in combination with the actual situation;
(2) the research on the classic and famous prescriptions of traditional Chinese medicine involving Gynecology, pediatrics, geriatrics and respiratory department is being carried out. It is planned to apply for listing permission after the relevant departments release the key information of the corresponding prescriptions;
(3) continue to carry out the clinical research of the key varieties of Kun Tai capsule, ningmo Tai capsule, Kushen gel and Prunella vulgaris oral liquid, and develop the related products for two times.
\u3000\u3000 4. Take multiple measures to complete the construction of marketing promotion project
Clinical sales is the company’s key marketing channel. Under the effective promotion of the equity incentive plan, promote the ability of channel development and strengthen the fine management of terminal business. In addition, the company has established a special variety marketing team to further explore the promotion of second-line varieties.
Breakthrough in OTC market development. By the end of 2021, the company’s OTC market has covered more than 90000 pharmacies in 30 provinces and cities across the country, an increase of 12% over 2020; It covers nearly 800 large and medium-sized mainstream drug chain companies and has continuously strengthened the cooperative relationship between the two sides. The unit yield of drug stores increased by 26.4% over 2020.
Increase the sales Investment in Internet channels, accelerate the construction and operation of media channels, especially the construction of new media, distribute and disseminate the company’s products through media channels, and accurately reach consumers. In 2022, OTC market sales may increase by more than 50%.
Research source 3 Joyoung Co.Ltd(002242) 022 record of investor relations activities on March 303 Zhejiang Xianju Pharmaceutical Co.Ltd(002332) 022 record of investor relations activities on March 30 Guiyang Xintian Pharmaceutical Co.Ltd(002873) 2022 record of investor relations activities on March 31;
(the content of this article comes from the announcement of listed companies and does not constitute any investment suggestions, nor does it represent the viewpoint of the platform. Investors are invited to make independent judgment and decision.)
